[
    {
        "id": 11,
        "drugName": "Rituximab",
        "fdaApprovalDate": "1997-11-26",
        "primaryIndication": "Non-Hodgkin Lymphoma, Rheumatoid Arthritis",
        "mechanism": "Anti-CD20 monoclonal antibody",
        "knownTargets": [
            "CD20"
        ],
        "adverseEvents": [
            "Infusion reactions",
            "Infections",
            "Progressive multifocal leukoencephalopathy"
        ],
        "pkSummary": "IV administration, Half-life ~22 days",
        "patentStatus": "Biosimilars available (2019)",
        "marketValue": "$7.5B annually"
    },
    {
        "id": 12,
        "drugName": "Atorvastatin",
        "fdaApprovalDate": "1996-12-17",
        "primaryIndication": "Hypercholesterolemia, Cardiovascular Disease Prevention",
        "mechanism": "HMG-CoA reductase inhibition",
        "knownTargets": [
            "HMG-CoA reductase"
        ],
        "adverseEvents": [
            "Myalgia",
            "Hepatotoxicity (rare)",
            "Rhabdomyolysis (rare)"
        ],
        "pkSummary": "Oral bioavailability ~14%, Half-life 14 hours",
        "patentStatus": "Expired (2011)",
        "marketValue": "$12.9B peak"
    },
    {
        "id": 13,
        "drugName": "Warfarin",
        "fdaApprovalDate": "1954-02-12",
        "primaryIndication": "Anticoagulation, DVT/PE Prevention",
        "mechanism": "Vitamin K epoxide reductase inhibition",
        "knownTargets": [
            "VKORC1"
        ],
        "adverseEvents": [
            "Bleeding",
            "Skin necrosis (rare)"
        ],
        "pkSummary": "Complete absorption, Half-life 20-60 hours",
        "patentStatus": "Public domain",
        "marketValue": "$500M annually"
    },
    {
        "id": 14,
        "drugName": "Acyclovir",
        "fdaApprovalDate": "1982-03-29",
        "primaryIndication": "Herpes Simplex, Varicella Zoster",
        "mechanism": "Viral DNA polymerase inhibition",
        "knownTargets": [
            "Viral thymidine kinase"
        ],
        "adverseEvents": [
            "Nausea",
            "Headache",
            "Renal dysfunction (IV)"
        ],
        "pkSummary": "Oral bioavailability ~15-30%, Half-life 2.5-3 hours",
        "patentStatus": "Expired",
        "marketValue": "$380M annually"
    },
    {
        "id": 15,
        "drugName": "Tamoxifen",
        "fdaApprovalDate": "1977-12-30",
        "primaryIndication": "Breast Cancer",
        "mechanism": "Selective estrogen receptor modulator",
        "knownTargets": [
            "ER-α"
        ],
        "adverseEvents": [
            "Hot flashes",
            "Endometrial cancer risk",
            "DVT"
        ],
        "pkSummary": "Well absorbed, Half-life 5-7 days",
        "patentStatus": "Expired",
        "marketValue": "$600M annually"
    },
    {
        "id": 16,
        "drugName": "Furosemide",
        "fdaApprovalDate": "1966-07-01",
        "primaryIndication": "Edema, Heart Failure, Hypertension",
        "mechanism": "Loop diuretic (Na-K-2Cl cotransporter inhibition)",
        "knownTargets": [
            "NKCC2"
        ],
        "adverseEvents": [
            "Hypokalemia",
            "Ototoxicity",
            "Dehydration"
        ],
        "pkSummary": "Oral bioavailability ~60%, Half-life 1.5-2 hours",
        "patentStatus": "Expired",
        "marketValue": "$250M annually"
    },
    {
        "id": 17,
        "drugName": "Allopurinol",
        "fdaApprovalDate": "1966-08-19",
        "primaryIndication": "Gout, Hyperuricemia",
        "mechanism": "Xanthine oxidase inhibition",
        "knownTargets": [
            "XO"
        ],
        "adverseEvents": [
            "Rash",
            "Stevens-Johnson syndrome (rare)",
            "Hepatotoxicity"
        ],
        "pkSummary": "Oral bioavailability ~80%, Half-life 1-2 hours (18-30 hours for oxypurinol)",
        "patentStatus": "Expired",
        "marketValue": "$180M annually"
    },
    {
        "id": 18,
        "drugName": "Fluoxetine",
        "fdaApprovalDate": "1987-12-29",
        "primaryIndication": "Depression, OCD, Bulimia",
        "mechanism": "Selective serotonin reuptake inhibition",
        "knownTargets": [
            "SERT"
        ],
        "adverseEvents": [
            "Insomnia",
            "Nausea",
            "Sexual dysfunction"
        ],
        "pkSummary": "Well absorbed, Half-life 1-3 days (4-6 days for norfluoxetine)",
        "patentStatus": "Expired (2001)",
        "marketValue": "$2.8B peak"
    },
    {
        "id": 19,
        "drugName": "Omeprazole",
        "fdaApprovalDate": "1989-09-19",
        "primaryIndication": "GERD, Peptic Ulcer",
        "mechanism": "Proton pump inhibition",
        "knownTargets": [
            "H+/K+-ATPase"
        ],
        "adverseEvents": [
            "Headache",
            "Diarrhea",
            "Increased infection risk (long-term)"
        ],
        "pkSummary": "Rapid absorption, Half-life 0.5-1 hour",
        "patentStatus": "Expired (2001)",
        "marketValue": "$5.7B peak"
    },
    {
        "id": 20,
        "drugName": "Sertraline",
        "fdaApprovalDate": "1991-12-30",
        "primaryIndication": "Depression, Anxiety, PTSD",
        "mechanism": "Selective serotonin reuptake inhibition",
        "knownTargets": [
            "SERT"
        ],
        "adverseEvents": [
            "Nausea",
            "Diarrhea",
            "Sexual dysfunction"
        ],
        "pkSummary": "Variable absorption, Half-life 26 hours",
        "patentStatus": "Expired (2006)",
        "marketValue": "$3.3B peak"
    },
    {
        "id": 21,
        "drugName": "Celecoxib",
        "fdaApprovalDate": "1998-12-31",
        "primaryIndication": "Arthritis, Pain",
        "mechanism": "Selective COX-2 inhibition",
        "knownTargets": [
            "COX-2"
        ],
        "adverseEvents": [
            "Cardiovascular events",
            "GI bleeding",
            "Renal dysfunction"
        ],
        "pkSummary": "Oral bioavailability unknown, Half-life 11 hours",
        "patentStatus": "Expired (2014)",
        "marketValue": "$3.1B peak"
    },
    {
        "id": 22,
        "drugName": "Montelukast",
        "fdaApprovalDate": "1998-02-20",
        "primaryIndication": "Asthma, Allergic Rhinitis",
        "mechanism": "Leukotriene receptor antagonist",
        "knownTargets": [
            "CysLT1"
        ],
        "adverseEvents": [
            "Headache",
            "Abdominal pain",
            "Neuropsychiatric events"
        ],
        "pkSummary": "Rapid absorption, Half-life 2.7-5.5 hours",
        "patentStatus": "Expired (2012)",
        "marketValue": "$5.5B peak"
    },
    {
        "id": 23,
        "drugName": "Amlodipine",
        "fdaApprovalDate": "1987-07-31",
        "primaryIndication": "Hypertension, Angina",
        "mechanism": "Calcium channel blocker",
        "knownTargets": [
            "L-type Ca2+ channels"
        ],
        "adverseEvents": [
            "Peripheral edema",
            "Flushing",
            "Headache"
        ],
        "pkSummary": "Oral bioavailability ~64-90%, Half-life 30-50 hours",
        "patentStatus": "Expired (2007)",
        "marketValue": "$1.5B annually"
    },
    {
        "id": 24,
        "drugName": "Levothyroxine",
        "fdaApprovalDate": "2002-08-06",
        "primaryIndication": "Hypothyroidism",
        "mechanism": "Thyroid hormone replacement",
        "knownTargets": [
            "TRα",
            "TRβ"
        ],
        "adverseEvents": [
            "Tachycardia",
            "Anxiety",
            "Osteoporosis (high doses)"
        ],
        "pkSummary": "Oral bioavailability ~70-80%, Half-life 7 days",
        "patentStatus": "Generic",
        "marketValue": "$1.8B annually"
    },
    {
        "id": 25,
        "drugName": "Lisinopril",
        "fdaApprovalDate": "1987-12-29",
        "primaryIndication": "Hypertension, Heart Failure",
        "mechanism": "ACE inhibition",
        "knownTargets": [
            "ACE"
        ],
        "adverseEvents": [
            "Cough",
            "Hyperkalemia",
            "Angioedema"
        ],
        "pkSummary": "Oral bioavailability ~25%, Half-life 12 hours",
        "patentStatus": "Expired (2002)",
        "marketValue": "$2.2B annually"
    }
]